AI Article Synopsis

  • A recent paper talks about how to make liquid biopsy, a type of cancer test, better and easier to use.
  • The recommendations focus on helping doctors and patients access these tests more easily.
  • This is important because liquid biopsies can help find and monitor cancer without needing surgery.

Article Abstract

We discuss a recent manuscript providing recommendations to improve use and access for liquid biopsy in oncology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830090PMC
http://dx.doi.org/10.1200/PO.23.00609DOI Listing

Publication Analysis

Top Keywords

access liquid
8
liquid biopsy
8
optimizing access
4
biopsy future
4
future cancer
4
cancer landscape
4
landscape discuss
4
discuss manuscript
4
manuscript providing
4
providing recommendations
4

Similar Publications

Cerebrospinal fluid (CSF) has emerged as a valuable liquid biopsy source for glioma biomarker discovery and validation. CSF produced within the ventricles circulates through the subarachnoid space, where the composition of glioma-derived analytes is influenced by the proximity and anatomical location of sampling relative to tumor, in addition to underlying tumor biology. The substantial gradients observed between lumbar and intracranial CSF compartments for tumor-derived analytes underscore the importance of sampling site selection.

View Article and Find Full Text PDF

Background: Insulin signaling deregulation in the brain is a critical risk factor for Alzheimer's disease (AD); however, molecular changes in this pathway during AD pathogenesis cannot be currently accessed in clinical setting due to lack of brain tissues. Here, we propose small extracellular vesicles (sEV) characterization as a non-invasive approach to assess the status of insulin signaling in the AD brain.

Method: In postmortem brain tissues of cognitively normal (CN) and AD (n=5 each) subjects, expression of 84 genes, involved in insulin signaling and resistance was analyzed using pathway specific PCR array.

View Article and Find Full Text PDF

Background: Down syndrome (DS, trisomy 21) is the most frequent genetic cause of intellectual disability (ID), prevalent in approximately 1 in 900 live births (Loane et al., 2013). People with DS are at high risk to develop Alzheimer's disease dementia (AD) (Lott & Head, 2001).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

SPEAR BIO INC, Woburn, MA, USA.

Background: Cutting-edge ultrasensitive immunoassay platforms have unveiled the potential of blood-based biomarkers, offering detection at low fg/mL levels for early neurodegenerative disorder prognosis, screening, and therapeutic monitoring. Current immunoassays, such as single molecule array (SIMOA) and mesoscale multi-array (MSD), face limited adoption due to their reliance on specialized equipment. Additionally, they require immobilization of probe reagents and a washing process, demanding tens of thousands of proteins to achieve the Limit of Detection (LOD), leading to the requirement of high sample volume and high affinity antibodies for fg/mL sensitivity.

View Article and Find Full Text PDF

While the conformational ensembles of disordered peptides and peptidomimetics are complex and challenging to characterize, they are a critical component in the paradigm connecting macromolecule sequence, structure, and function. In molecules that do not adopt a single predominant conformation, the conformational ensemble contains rich structural information that, if accessible, can provide a fundamental understanding related to desirable functions such as cell penetration of a therapeutic or the generation of tunable enzyme-mimetic architecture. To address the fundamental challenge of describing broad conformational ensembles, we developed a model system of peptidomimetics comprised of polar glycine and hydrophobic -butylglycine to characterize using a suite of analytical techniques.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!